Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.

A live and archived webcast will be available in the Investors > Events section of the company website.

Argus May 27 session

+1.22% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – IRD

On May 27, the day this news came out, IRD closed 1.22% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Key Figures

Conference time: 8:45 a.m. ET

Conference time

8:45 a.m. ET

Jefferies Global Healthcare Conference presentation on June 3, 2026

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Conference appearance

   24h Move

   -2.9%

   RBC Global Healthcare Conference presentation announcement for May 19, 2026.

2. May 12

   Earnings and update

   24h Move

   +1.2%

   Q1 2026 results with cash runway, losses, and pipeline timelines.

3. May 07

   Clinical data update

   24h Move

   -6.9%

   ARVO 2026 data showing early functional gains in IRD programs.

4. May 07

   Trial enrollment

   24h Move

   +1.9%

   Completion of Cohort 1 enrollment in OPGx‑BEST1 Phase 1/2 study.

5. May 04

   Regulatory program

   24h Move

   -0.4%

   FDA acceptance of OPGx‑LCA5 into the RDEP program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gene therapies, inherited retinal diseases

2 terms

gene therapies medical

"a clinical-stage biopharmaceutical company developing gene therapies to restore vision"

Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.

inherited retinal diseases medical

"prevent blindness in patients with inherited retinal diseases (IRDs)"

Inherited retinal diseases are a group of genetic conditions in which errors in the genes that build and maintain the light-sensing cells at the back of the eye cause progressive vision loss or blindness; think of it as faulty wiring in a camera that gradually degrades the picture. They matter to investors because they define a clear patient population with high unmet need, driving demand for diagnostics and novel treatments (gene, cell or drug therapies) that can produce long-term revenue, regulatory milestones and intellectual property value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Opus Genetics (IRD) present at the 2026 Jefferies Global Healthcare Conference?

Opus Genetics will present on Wednesday, June 3, 2026 at 8:45 a.m. ET. According to the company, this appearance is part of the 2026 Jefferies Global Healthcare Conference agenda.

How can investors watch the Opus Genetics (IRD) webcast from the 2026 Jefferies conference?

Investors can access a live and archived webcast through the Opus Genetics website. According to the company, it is available under the Investors section, within the Events page.

What type of company is Opus Genetics (Nasdaq: IRD)?

Opus Genetics is a clinical-stage biopharmaceutical company focused on gene therapies. According to the company, its programs aim to restore vision and prevent blindness in patients with inherited retinal diseases.

What is the focus of Opus Genetics’ gene therapy programs mentioned with IRD stock?

Opus Genetics develops gene therapies targeting inherited retinal diseases that cause vision loss. According to the company, its goal is to restore vision and prevent blindness in affected patient populations.

Where is Opus Genetics (IRD) headquartered?

Opus Genetics is headquartered in Research Triangle Park, North Carolina. According to the company, this location serves as its base for developing gene therapies for inherited retinal diseases.

Will the Opus Genetics (IRD) 2026 Jefferies presentation be available after the live event?

Yes, an archived webcast will be available after the live presentation. According to Opus Genetics, investors can access the replay via the Investors section of its website, under Events.